S.E.E.D. Planning Group LLC Arcutis Biotherapeutics, Inc. Transaction History
S.E.E.D. Planning Group LLC
- $329 Million
- Q3 2025
A detailed history of S.E.E.D. Planning Group LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, S.E.E.D. Planning Group LLC holds 13,000 shares of ARQT stock, worth $271,440. This represents 0.07% of its overall portfolio holdings.
Number of Shares
13,000Holding current value
$271,440% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding ARQT
# of Institutions
247Shares Held
131MCall Options Held
407KPut Options Held
216K-
Suvretta Capital Management, LLC New York, NY11.5MShares$241 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$232 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$224 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$206 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$180 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.26B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...